---
title: "Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294463160.md"
description: "Myriad Genetics (NASDAQ:MYGN) shares plummeted 37.80% in after-hours trading following weak Q2 2026 results, including an $11% revenue drop to $190.7 million, a $38.9 million operating loss, and reduced full-year guidance. Despite a regular session gain, the stock fell sharply due to lower prenatal testing demand and suspended EBITDA outlooks, though its Cancer Care Continuum business saw volume growth."
datetime: "2026-07-31T05:48:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294463160.md)
  - [en](https://longbridge.com/en/news/294463160.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294463160.md)
generator: "portal-rs"
---

# Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know

**Myriad Genetics Inc.** (NASDAQ:MYGN) shares plunged 37.80% in Thursday’s after-hours session after the company reported second-quarter 2026 financial results that included lower revenue, an operating loss, reduced full-year revenue guidance and the suspension of its adjusted EBITDA outlook.

The stock closed Thursday’s regular session up 6.55% at $5.37 before falling 37.80% to $3.34 in after-hours trading.

Myriad Genetics develops molecular diagnostic tests and precision medicine products that help assess disease risk and guide treatment decisions.

## Quarterly Results

Myriad reported second-quarter revenue of $190.7 million, down 11% from a year earlier, as lower prenatal testing demand and reduced average revenue per test weighed on results. The company posted an operating loss of $38.9 million and lowered its full-year 2026 revenue guidance while suspending its adjusted EBITDA guidance.

Despite the weaker quarter, Myriad said its Cancer Care Continuum business continued to grow, with test volumes increasing 6% year over year. The company also launched new products and is rolling out its “Ascend” initiative, which focuses on improving efficiency, productivity and long-term profitability.

“Our second quarter 2026 performance fell short of our expectations,” CEO **Sam Raha** said, adding that the company is taking actions to improve reimbursement, increase efficiency and strengthen its financial performance.

 **Read Also: Splash Beverage Group (SBEV) Stock Is Trending Overnight— Here's Why It Jumped 64% After Hours** 

## Trading Metrics

Myriad Genetics has a market capitalization of approximately $507.19 million, with a 52-week high of $8.59 and a 52-week low of $3.53.

Over the past 12 months, MYGN shares have gained approximately 39.84%.

**Benzinga Edge Stock Rankings** show positive price trends across the short- and medium-term time frames, while the long-term trend remains negative.

***Disclaimer:** This content was produced with the help of AI tools and was reviewed and published by Benzinga editors.*

 **Read Also: Karyopharm Stock (KPTI) Crashes After Hours: Here's What's Driving the Move** 

*Photo Courtesy: Kumotion on Shutterstock.com*

### Related Stocks

- [MYGN.US](https://longbridge.com/en/quote/MYGN.US.md)
- [SBEV.US](https://longbridge.com/en/quote/SBEV.US.md)
- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)
- [SBEV+.US](https://longbridge.com/en/quote/SBEV+.US.md)
- [SBEVW.US](https://longbridge.com/en/quote/SBEVW.US.md)

## Related News & Research

- [Myriad Q2 revenue misses estimates, cuts 2026 revenue outlook](https://longbridge.com/en/news/294411320.md)
- [VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase](https://longbridge.com/en/news/296932909.md)
- [VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision](https://longbridge.com/en/news/296815081.md)
- [Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet.](https://longbridge.com/en/news/296643850.md)
- [Biovica says DiviTum TKa study in metastatic melanoma is published in Clinical Cancer Research](https://longbridge.com/en/news/296871354.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**